Adult Dosing
Fingernail onchomycoses
Toenail onchomycoses
Tinea capitis (use oral granules)
- < 25 kgs: 125 mg/day PO x 6 wks
- 25-35 kgs: 187.5 mg/day PO x 6 wks
- > 35 kgs: 250 mg/day PO x 6 wks
Tinea corporis/Tinea cruris (Not FDA approved)
Note: Confirm diagnosis before starting therapy
Pediatric Dosing
Tinea capitis
Child > 4 yrs (use oral granules)
- < 25 kgs: 125 mg/day PO x 6 wks
- 25-35 kgs: 187.5 mg/day PO x 6 wks
- > 35 kgs: 250 mg/day PO x 6 wks
Note:
- Confirm diagnosis before starting therapy
- The safety and efficacy of LAMISIL® tablets have not been established in pediatric patients
[Outline]
Renal Dose Adjustment (Based on CrCl)
Hepatic Dose Adjustment
- Active or chronic hepatic impairment: Use not recommended
See Supplemental Patient Information
- Rare cases of fatal liver failure have occurred with the use of oral terbinafine. Hepatotoxicity may occur in patients with and without pre-existing liver disease. Obtain pretreatment serum transaminase (ALT and AST) levels
- Taste disturbance, including ageusia of varying severity may occur with terbinafine use. Discontinue therapy if taste disturbance occurs
- Smell disturbance, including anosmia of varying severity may occur with terbinafine use. Discontinue therapy if smell disturbance occurs
- Depressive symptoms may occur with terbinafine use
- Transient increases in absolute lymphocyte counts have been observed. Severe neutropenia has also been reported. If the neutrophil count is < 1,000 cells/mm3 discontinue therapy
- Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome have been reported with oral terbinafine use. If symptoms of drug reaction are observed, discontinue treatment
- Precipitation and exacerbation of cutaneous and systemic lupus erythematosus may occur
Cautions: Use cautiously in
- Immunodeficiency
- SLE
- Psoriasis
- Lactation
Supplemental Patient Information
- Advise patients to promptly report any symptoms of persistent nausea, anorexia, fatigue, vomiting, right upper abdominal pain or jaundice, dark urine or pale stools
Pregnancy Category:B
Breastfeeding: Limited information indicates that oral maternal doses of 500 mg/day produce low levels in milk. Terbinafine would not be expected to cause any adverse effects in breastfed infants, especially if the infant is > 2 months. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 28 April 2010). According to manufacture's data, terbinafine is excreted in breastmilk and achieves concentration seven times that of plasma concentrations. Use not recommended.
US Trade Name(s)
US Availability
terbinafine (generic)
Lamisil
- TABS: 250 mg
- GRAN: 125 mg/packet
- GRAN: 187.5 mg/packet
Canadian Trade Name(s)
Canadian Availability
terbinafine (generic)
Lamisil
UK Trade Name(s)
UK Availability
terbinafine (generic)
Lamisil
Australian Trade Name(s)
- Lamisil
- Sebifin
- Tamsil
- Terbihexal
- Zabel
Australian Availability
terbinafine (generic)
Lamisil, Sebifin, Tamsil, Terbihexal, Zabel
[Outline]
Pricing data from www.DrugStore.com in U.S.A.
- LamISIL 250 MG TABS [Bottle] (NOVARTIS)
30 mg = $534
90 mg = $1546.01
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
